As data is limited, to determine national estimates and characteristics of Alzheimer's disease and senile dementia (ADϩSD) visits in the United States (US) ambulatory setting. METHODS: Through a retrospective analysis of the 10year (1998-2007) physician-office visit data of National Ambulatory Medical Care Survey, we calculated weighted national estimates and percentages of ADϩSD visits made by patients aged 40 years and older with relevant ICD-9CM codes (290.xx, 294.xx, 331.xx). In multivariate logistic regression we analyzed the characteristics associated with anti-dementia drug mention at ADϩSD visits. RESULTS: Of an estimated 6.5 million adult ambulatory care visits (5 visits per 1000 people) for ADϩSD, 52%, 25%, 20%, 14%, and 11%, mentioned an antidementia (memantine, cholinesterase inhibitor, or donepezil/rivastigmine/gallantamine), anticholinergic, antidepressant, antipsychotic, and antianxiety drug respectively. Patients with ADϩSD visits were predominantly 75-84 year olds (53%), white (89%), female (63%), living in metropolitan statistical area (81%), South (30%) and Northeast (28%), on Medicare (73%), seeing a freestanding private practice physician (61%) or a neurologist (32%), established patient (88%), and reported hypertension (12%). In multivariate analyses controlling for gender, type of dementia, comorbidity, and visityear, any versus no anti-dementia drug mention was significantly less likely at visits by other versus white-race patients (adjusted odds ratio [OR] ϭ is 0.44,95%CI: 0.42-0.46), new versus established patients (ORϭ0.38;95%CI:0.37-0.39), by those on self-pay versus private-insurance (ORϭ0.63;95%CI:0.56 -0.70), and in South (ORϭ0.43;95%CI:0.41-0.44) and West (ORϭ0.41;95%CI:0.40 -0.43) versus those in Northeast (all P Ͻ0.0001). CONCLUSIONS: About 50% and 25% of ADϩSD visits mentioned an anti-dementia drug and other drugs, respectively. New patients, those of other races, on self-pay and living in South or West of the US were less likely to receive an anti-dementia drug. Study findings' suggest deficiencies in access and quality of dementia care in the US warranting the attention of providers and payers and need further study.
INTRODUCTION Although benzodiazepines are primarily considered anxiolytics, some have other indications such as seizures, insomnia, alcohol withdrawal, and tardive dyskinesia. They are also commonly abused medications, especially the brand name products, alone and in combination with other drugs (e.g. methadone). They are classified, on the basis of their half lives, into short-, intermediate-and long-acting agents. The side effects of falling and fractures cause benzodiazepines to be unattractive for elderly patients. OBJECTIVES: To describe trends in the utilization of, spending on, and average per-prescription spending on benzodiazepines, individually, stratified by half life, and overall, for the U.S. Medicaid programs over the past two decades. METHODS: A retrospective, descriptive analysis was performed using the national Medicaid pharmacy claims database, which has information on outpatient prescription claims. Quarterly prescription counts and reimbursement amounts were calculated for each of the benzodiazepines (branded or generic) reimbursed by Medicaid. Average per-prescription spending was found by dividing reimbursement by the number of prescriptions. RESULTS: Prescriptions for benzodiazepines among Medicaid beneficiaries increased from 6.15 million in 1991 to 16.70 million in 2009. Expenditures rose from $108.75 million to $165.79 million over the same time period, implying an average per-prescription price of approximately $10 in 2009. Whereas utilization of long-acting agents remained relatively constant at 1.79 million prescriptions per year, prescriptions for short-acting and intermediate-acting drugs rose from 1.74 million to 4.94 million, and from 2.82 million to 9.91 million, respectively. Prescriptions for flurazepam have fallen steadily from 439,106 in 1991 to 45,754 in 2009. CONCLUSIONS: Spending on benzodiazepines represents Ͻ 1% of Medicaid's spending on outpatient drugs. Moreover, due to generic entry for some of the drugs, the percentage rise in spending on benzodiazepines since 1991 (52.5%) was less than the general rate of inflation (57.5%). By its policy of reimbursing for generic, rather than branded, prescriptions, Medicaid reduces the opportunity for abuse.
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RISK-BENEFIT ANALYSIS OF DEPRESSION TREATMENT FOR CHILDREN AND YOUNG ADULTS
Soeteman DI, Miller M, Kim J Harvard School of Public Health, Boston, MA, USA OBJECTIVES: The U.S. Food and Drug Administration's decision to mandate a blackbox warning on antidepressants indicating that they are associated with an increased risk of suicidal behavior in children and young adults remains controversial. We aimed to quantify the tradeoffs of alternative strategies in treating pediatric major depressive disorder (MDD) with respect to clinical benefit and risk of fatal and nonfatal suicidal behavior over a five-year time horizon. METHODS: We developed a disease simulation model integrating epidemiological and clinical data from the published literature in order to simulate the effect of three treatment strategies (i.e., Selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a combination of SSRIs and CBT) on a U.S. population of children and young adults with MDD. We explored the implications of different scenarios of data extrapolation beyond the time horizon of existing data and of uncertain assumptions about suicide attempt risks and patients' response to treatment. Main outcome measures were symptom-free weeks, suicide attempts, and suicide deaths. RESULTS: In a cohort of 1,000,000 simulated children and young adults, there were more than twice as many suicide deaths among those started on SSRIs (1291), compared to those started on CBT (506) or combination treatment (621) over the first 36 weeks of treatment. Over a five-year time horizon, this hierarchy of suicide risk persisted, even under assumptions most favorable to SSRIs. With respect to symptom-free weeks, combination treatment was superior to both SSRIs and CBT alone, but this difference was marginal over a five-year time horizon. CONCLUSIONS: Considering the risk-benefit profile over a five-year period, CBT appears to offer a safer profile with respect to suicide deaths and attempts than combination treatment or SSRIs alone. While combination treatment maximizes symptom-free weeks, the additional benefit over the five-year time horizon is modest and must be weighed against the clinically meaningful increase in fatal suicides.
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COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA BASED ON PRODUCT LABELS WITH ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE
Parente AK, Wang RH, Jones BT MedAssurant, Bowie, MD, USA OBJECTIVES: Physicians often make dosage decisions based on experience and heuristic factors in addition to the product label. This makes it difficult for economists to compare the "real world" costs and benefits of alternative therapeutic choices. We compare a published methodology for calculating therapeutic dose equivalence based on approved labeling for varous antipsychotics prescribed for schizophrenia with actual prescription data in that population. METHODS: The sample consisted of a proportional selection of patients that derived from a population of patients of all ages, across all payers, and in all regions of the United States. The information included NDC code sets, quantity, and day of supply and was aggregated from pharmaceutical prescriptions files. The frequency distribution measured the top antipsychotic medications in patients diagnosed with schizophrenia. The therapeutic dose equivalence was determined using the methodology of Woods (2003) as the comparator. RESULTS: A total of 324,724 patients with a diagnosis of schizophrenia were included in the study. Doses equivalent to 1 mg/day of Risperidone were 86.17 mg/day of Quetiapine, 5.09 mg/day of Olanzapine, 5.25 mg/day of Aripiprazole, 92.28 mg/day of Clozapine, and 33.74 mg/day of Ziprasidone. CONCLUSIONS: With the ever-increasing array of differntially-dosed medications available, it is imperative for physicians and outcomes researchers to utilize estimation of therapeutic dose equivalence that reflects actual practice patterns so that informed decisions can be made evaluating the cost and cost-effectiveness of various therapeutic choice. Our study enables pharmacoeconomic comparisons among antispychotics not only according to label-approved dosages, but also real-world dosing patterns.
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EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP'S) ON OPIOID OVERDOSE ADMISSION
Painter JT University of Kentucky, Lexington, KY, USA OBJECTIVES: Over the past three decades the concept of prescription monitoring programs (PMPs) has developed immensely, however little evidence regarding their effectiveness has been collected. This study focuses on simple difference-indifference evaluations, comparing the implementation effect of a PMP in Tennessee with Kentucky, which has a well-established PMP, and Missouri, which has not to-date enacted legislation to develop a PMP. The effect of interest is opioid overdose hospital admission. METHODS: The present study examines a simple difference-in-difference model of a natural experiment caused by the staggered implementation of prescription monitoring programs in Kentucky, Missouri, and Tennessee. We implement a pre-post design with the primary outcome of interest being hospital admission due to opioid overdose. For this evaluation we use all claims from Kentucky, Missouri, and Tennessee in the HCUP-NIS data from 2006 and 2008. The data is separated according to whether the hospital admission was due to opioid overdose. Four models are examined: main effects, individual fixed effects, and the full model, which takes into account both year and state fixed effects and shows the true effect of the Tennessee implementation. Although the findings in the Tennessee models trend positively, there are no significant findings in the full model. RESULTS: We look at various models, including fixed effects for state and year, but no consistently significant effect is seen. Despite no statistically significant findings, coefficients do trend in expected directions suggesting a sound model. CONCLUSIONS: There are multiple possible reasons for the lack of significant findings, including several study limitations. Despite the limitations, it can be said that the Controlled Substance Abuse Database Program in Tennessee has no A197 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
